Efficacy, safety, and tolerability of ubrogepant in the treatment of acute migraine among migraine patients in Hail City, Saudi Arabia: A retrospective case
Abstract
ABSTRACT Migraines represent a significant health burden globally and are particularly prevalent in Saudi Arabia, with rates exceeding the global average. Effective management of acute migraine attacks is crucial for improving patient outcomes. Ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, has shown promise in treating acute migraines. While previous research has confirmed its efficacy and safety in different populations, there is a lack of localized data evaluating its use among patients in Saudi Arabia. To evaluate the efficacy, safety, and tolerability of Ubrogepant 100 mg for acute migraine management among patients in Hail City, Saudi Arabia. This retrospective case series included all patients prescribed Ubrogepant 100 mg for acute migraine attacks. Eligible patients were identified through electronic medical records and contacted via patient portal, phone, or clinic visits to complete a 15-item open-ended questionnaire. The survey assessed treatment response, safety, and tolerability of Ubrogepant. Among 27 migraine patients treated with Ubrogepant, nearly 70% achieved complete headache resolution within 2 hours, and 80% experienced significant migraine relief within 1.5 hours. Functional disability scores significantly improved (P = .001), and associated symptoms such as photophobia and nausea also declined. While nearly half (48%) experienced mild side effects, mostly fatigue, more than half reported no adverse events. Ubrogepant 100 mg…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 27 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.